A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

AbbVie

Status and phase: Completed; Phase 2

Conditions: Hepatitis C Virus Infection

Treatments: Drug: ABT-072

Study type: Interventional

Funder types: Industry

Identifiers

NCT00872196

M10-605

Details and patient eligibility

About

This is a follow-up study with no treatment and only samples being collected.

Full description

The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.

Enrollment: 5 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072.

Exclusion criteria

• The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical study.

Trial design

5 participants in 1 patient group

1 - Follow-up Study

Other group

Description:

This is a follow-up study with no treatment and only samples being collected.

Treatment:

Drug: ABT-072